Abstract: Objective To evaluate the efficacy and safety of gatifloxacin in the treatment of acquired lower respiratory tract infection in community.Methods A prospective,non-comparator control,open-label drug clinical trial of phase Ⅳ was conducted.The dosage of gatifloxacin was 4000mg,once daily orally.The duration of treatment was 7～14 d.Results Totally 36 cases with community acquired lower respiratory tract infection were enrolled in Beijing Tiantan hospital from February 2004 to February 2005.34 patients were assessable for safety and 31 patients assessable for efficacy.The mean age of the patients was 44.8 years old(23～69 years).There were 18 patients with pneumonia and 13 patients with chronic bronchitis.The results showed that the overall efficacy rate was 93.5%,whereas the bacterial clearance rate was 100%.The rate of adverse drug reaction was 11.8%.Conclusion It is both effective and safe with oral gatifloxacin once daily to treat community acquired lower respiratory tract infection.

Key words: gatifloxacin, lower respiratory tract infection, community acquired